Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20666032 | 0.73 | TP53 (0.42) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL1487981 | 0.72 | — | — | |
| SCHEMBL14304537 | 0.71 | GAA (0.46) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL20283447 | 0.71 | L3MBTL1 (0.42) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL23848857 | 0.71 | POLB (0.43) | MAPTMEN1KMT2ARAB9ATSHR | |
| SCHEMBL25078194 | 0.71 | RAB9A (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4164253 | 0.71 | MAPT (0.47) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL31482338 | 0.71 | LMNA (0.53) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL31498989 | 0.71 | TSHR (0.60) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL8663534 | 0.71 | LMNA (0.53) | MAPTMEN1KMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2820013-B9 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS INC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-8158389-B2 | Products and methods for in vivo secretion of monatin | CARGILL, INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| US-8153405-B2 | Products and methods for in vivo secretion of monatin | CARGILL, INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| EP-1883817-A2 | PRODUCTS AND METHODS FOR IN VIVO SECRETION OF MONATIN | Cargill, Incorporated (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070105938-A1 | Products and Methods for In Vivo Secretion of Monatin | CARGILL, INCORPORATED (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070099277-A1 | Products and methods for in vivo secretion of monatin | CARGILL, INCORPORATED (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2006113897-A2 | PRODUCTS AND METHODS FOR IN VIVO SECRETION OF MONATIN | CARGILL, INCORPORATED (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105938-A1 | Products and Methods for In Vivo Secretion of Monatin | MON2, MLEC, STOM | MAPT 4270/4885MEN1 7/4885KMT2A 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.